Jump to content

Northfield Laboratories: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Citation bot (talk | contribs)
Alter: title. | Use this bot. Report bugs. | Suggested by Abductive | Category:Companies formerly listed on the Nasdaq | #UCB_Category 676/712
m top: clean up, removed: | ISIN2 =
Line 19: Line 19:
| traded_as =
| traded_as =
| ISIN =
| ISIN =
| ISIN2 =
| industry =
| industry =
| genre =
| genre =

Revision as of 02:25, 17 December 2022

Northfield Laboratories Inc.
Founded1985
DefunctMay 9, 2009 (2009-05-09)
Headquarters
ProductsPolyHeme

Northfield Laboratories Inc. ( former NASDAQ: NFLD ) was the maker of PolyHeme, a hemoglobin-based oxygen carrier (HBOC). The company was based in Evanston, Illinois, with Dr. Steven A. Gould as its chief executive officer. As of May 31, 2005, the company had 68 employees.

It was founded in 1985 and has since been a mainly research and development company. Northfield's only product was PolyHeme, an oxygen-carrying blood substitute, which failed to receive Food and Drug Administration (FDA) regulatory approval. On May 9, 2009, after being informed by the FDA the product's risks outweighed the benefits, the company shut down operations. During their operations, they incurred losses of about 220 million dollars.[1] The corporation was also criticized for some design elements of its clinical trials related to the need to perform critical care and resuscitation while patients were in grave clinical conditions due to the mechanisms of injury incurred and the consequent inability of patients to provide informed consent for treatment.[2]

See also

References

  1. ^ "Business News". www.chicagotribune.com. Retrieved May 9, 2009.Template:SemiBareRefNeedsTitle
  2. ^ http://blogs.abcnews.com/theblotter/2007/05/test_of_controv.html